COVID-19NCT06620159
Lymphocyte to Procalcitonin Ratio in Covid-19 Patients
An observational study of COVID-19, run by Suleyman Demirel University at 1 site in Turkey (Türkiye).
Trial summary
The lymphocyte/CRP ratio has been studied many times in covid-19 patients and has been proven to be an indicator of mortality as well as poor prognosis. In this study, the role of the lymphocyte/procalcitonin ratio in predicting the hospitalization status of patients, detection of findings on CT, need for mechanical… Read more about this study
- Who is it for?
- Ages 23 to 100 years
- Conditions the study is for
- COVID-19
- How many people
- 535 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Apr 2020to 1 Dec 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 23 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients over 18 years of age who applied to suleyman demirel university emergency department and diagnosed with covid 19 by PCR
Who may be able to join
- Covid19 PCR test positive
Who cannot join
- Pregnancy Under 18 years old
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Süleyman demirel üniversitesi tıp fakültesi
Isparta, 32200
About this study
Official title: Lymphocyte to Procalcitonin Ratio: A New Predictor of Prognosis and Mortality in Covid
The lymphocyte/CRP ratio has been studied many times in covid-19 patients and has been proven to be an indicator of mortality as well as poor prognosis. In this study, the role of the lymphocyte/procalcitonin ratio in predicting the hospitalization status of patients, detection of findings on CT, need for mechanical ventilation, mortality and survival is aimed to be determined. The lymphocyte/procalcitonin ratio was found to be the strongest predictor of mortality and poor prognosis, especially in patients over 65 years of age.
Read the detailed description
The lymphocyte/CRP ratio has been studied many times in covid-19 patients and has been proven to be an indicator of mortality as well as poor prognosis. In this study, the role of the lymphocyte/procalcitonin ratio in predicting the hospitalization status of patients, detection of findings on CT, need for mechanical ventilation, mortality and survival is aimed to be determined. The lymphocyte/procalcitonin ratio was found to be the strongest predictor of mortality and poor prognosis, especially in patients over 65 years of age. The auc value, PPV and specificity of the lymphocyte/procalcitonin ratio were higher than the lymphocyte/CRP ratio.
- Conditions
- COVID-19
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Covid19(+) | Covid19 patients with a positive PCR test |
What is being measured
The primary outcome is the main question the study is designed to answer.
outcome
The relationship between lymphocyte/procalcitonin ratio and 30-day mortality was analyzed.
Measured: 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Oct 2024
- Study start1 Apr 2020
- Primary completion27 Sep 2024
- Study completion1 Dec 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COVID-19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 535 participants (actual)
Sponsor and investigators
- Lead sponsor
- Suleyman Demirel University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Teslime Eryavuz Şengül, Suleyman Demirel University
- Investigators
- Furkan Ç Oğuzlar, asst. prof., Principal investigator, suleyman demirel university faculty of medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06620159
- Sponsor's protocol ID
- SuleymanDU-MED-TEŞ-02
- Status last verified
- Oct 2024
- First submitted
- 27 Sep 2024
- Last updated
- 3 Oct 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Lymphocyte to Procalcitonin Ratio: A New Predictor of Prognosis and Mortality in Covid
- ClinicalTrials.gov ID
- NCT06620159
- Acronym / sponsor ID
- SuleymanDU-MED-TEŞ-02
- Conditions
- COVID-19
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 535 participants (actual)
- Lead sponsor
- Suleyman Demirel UniversityUniversity, hospital or other
- Study start
- 1 Apr 2020 (actual)
- Primary completion
- 27 Sep 2024 (actual)
- Study completion
- 1 Dec 2024 (estimated)
- First posted
- 1 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The lymphocyte/CRP ratio has been studied many times in covid-19 patients and has been proven to be an indicator of mortality as well as poor prognosis. In this study, the role of the lymphocyte/procalcitonin ratio in predicting the hospitalization status of patients, detection of findings on CT, need for mechanical ventilation, mortality and survival is aimed to be determined. The lymphocyte/procalcitonin ratio was found to be the strongest predictor of mortality and poor prognosis, especially in patients over 65 years of age.
Detailed description
The lymphocyte/CRP ratio has been studied many times in covid-19 patients and has been proven to be an indicator of mortality as well as poor prognosis. In this study, the role of the lymphocyte/procalcitonin ratio in predicting the hospitalization status of patients, detection of findings on CT, need for mechanical ventilation, mortality and survival is aimed to be determined. The lymphocyte/procalcitonin ratio was found to be the strongest predictor of mortality and poor prognosis, especially in patients over 65 years of age. The auc value, PPV and specificity of the lymphocyte/procalcitonin ratio were higher than the lymphocyte/CRP ratio.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Covid19(+) | – | –Covid19 patients with a positive PCR test |
Who may qualify
- Ages
- 23 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients over 18 years of age who applied to suleyman demirel university emergency department and diagnosed with covid 19 by PCR
Key inclusion criteria (1 listed)
- Covid19 PCR test positive
Key exclusion criteria (1 listed)
- Pregnancy Under 18 years old
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
outcome
Time frame: 30 days
The relationship between lymphocyte/procalcitonin ratio and 30-day mortality was analyzed.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Oct 2024.
- Individual participant dataSharing planned: No
Related trials for COVID-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Furkan Ç Oğuzlar, asst. prof. principal investigator
suleyman demirel university faculty of medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID-19, run by Suleyman Demirel University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 3 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
outcome (time frame: 30 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Oct 2024.